NCT04500860View on ClinicalTrials.gov

Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.

PHASE1CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence
Interventions
DRUG

Low dose tadalafil 5 mg

Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence

DRUG

Tolterodine 4 Mg Oral Capsule, Extended Release

To compare efficacy of low dose tadalafil 5 mg to tolterodine 4 mg extended release in treatment of female overactive bladder

DRUG

Placebo

Placebo drugs

Trial Locations (1)

12334

Samer Morsy, Cairo

All Listed Sponsors
lead

Kasr El Aini Hospital

OTHER

NCT04500860 - Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up. | Biotech Hunter | Biotech Hunter